Childhood medulloblastoma
Standard
Childhood medulloblastoma. / Massimino, Maura; Biassoni, Veronica; Gandola, Lorenza; Garrè, Maria Luisa; Gatta, Gemma; Giangaspero, Felice; Poggi, Geraldina; Rutkowski, Stefan.
In: CRIT REV ONCOL HEMAT, Vol. 105, 09.2016, p. 35-51.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Childhood medulloblastoma
AU - Massimino, Maura
AU - Biassoni, Veronica
AU - Gandola, Lorenza
AU - Garrè, Maria Luisa
AU - Gatta, Gemma
AU - Giangaspero, Felice
AU - Poggi, Geraldina
AU - Rutkowski, Stefan
N1 - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
PY - 2016/9
Y1 - 2016/9
N2 - Medulloblastoma accounts for 15-20% of childhood nervous system tumours. The risk of dying was reduced by 30% in the last twenty years. Patients are divided in risk strata according to post-surgical disease, dissemination, histology and some molecular features such as WNT subgroup and MYC status. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those with disseminated and/or residual disease, large cell and/or anaplastic histotypes, MYC genes amplification. Current and currently planned clinical trials will: (1) evaluate the feasibility of reducing both the dose of craniospinal irradiation and the volume of the posterior fossa radiotherapy (RT) for those patients at low biologic risk, commonly identified as those having a medulloblastoma of the WNT subgroup; (2) determine whether intensification of chemotherapy (CT) or irradiation can improve outcome in patients with high-risk disease; (3) find target therapies allowing tailored therapies especially for relapsing patients and those with higher biological risk.
AB - Medulloblastoma accounts for 15-20% of childhood nervous system tumours. The risk of dying was reduced by 30% in the last twenty years. Patients are divided in risk strata according to post-surgical disease, dissemination, histology and some molecular features such as WNT subgroup and MYC status. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those with disseminated and/or residual disease, large cell and/or anaplastic histotypes, MYC genes amplification. Current and currently planned clinical trials will: (1) evaluate the feasibility of reducing both the dose of craniospinal irradiation and the volume of the posterior fossa radiotherapy (RT) for those patients at low biologic risk, commonly identified as those having a medulloblastoma of the WNT subgroup; (2) determine whether intensification of chemotherapy (CT) or irradiation can improve outcome in patients with high-risk disease; (3) find target therapies allowing tailored therapies especially for relapsing patients and those with higher biological risk.
KW - Journal Article
KW - Review
U2 - 10.1016/j.critrevonc.2016.05.012
DO - 10.1016/j.critrevonc.2016.05.012
M3 - SCORING: Journal article
C2 - 27375228
VL - 105
SP - 35
EP - 51
JO - CRIT REV ONCOL HEMAT
JF - CRIT REV ONCOL HEMAT
SN - 1040-8428
ER -